Opus Genetics (IRD) Capital Expenditures Growth (3y) (2013 - 2019)
Opus Genetics (IRD) Capital Expenditures Growth (3y) (2013 - 2019) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -12.25% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Opus Genetics | 3.27 Mn | -56.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 140.66% |
| Jun 30, 2019 | 28.62% |
| Mar 31, 2019 | 42.08% |
| Sep 30, 2018 | -3.78% |
| Jun 30, 2018 | -39.77% |
| Mar 31, 2018 | -31.77% |
| Dec 31, 2017 | 69.26% |
| Sep 30, 2017 | -39.91% |
| Jun 30, 2017 | 10.12% |
| Mar 31, 2017 | 1.69% |
| Dec 31, 2016 | -52.20% |
| Sep 30, 2016 | -74.41% |
| Jun 30, 2016 | 42.85% |
| Mar 31, 2016 | 96.15% |
| Dec 31, 2014 | -1.57% |
| Sep 30, 2014 | 91.86% |
| Jun 30, 2014 | 69.25% |
| Dec 31, 2013 | 34.93% |
| Sep 30, 2013 | 291.57% |